To evaluate the association between dupilumab treatment and lymphoma risk in patients with atopic dermatitis (AD) and other type 2 inflammatory diseases.
Key Findings:
AD increases the risk of lymphoma, including cutaneous T-cell lymphoma and non-Hodgkin lymphoma.
Dupilumab treatment did not alter lymphoma risk in AD patients but showed a tendency towards reduced risk, particularly in nondermatologic type 2 inflammatory diseases.
Interpretation:
The findings suggest that dupilumab does not increase lymphoma risk and may reduce the risk of non-Hodgkin lymphoma compared to other systemic treatments.
Limitations:
Retrospective nature of the analysis.
Quality of the data may affect results.
Potential for false registration of ICD-10 codes.
Conclusion:
The study supports the safety of dupilumab, indicating no association with increased lymphoma risk and potential lower rates of non-Hodgkin lymphoma in treated patients.
